百日咳博德特氏菌重新出现，包括一个耐大环内酯的分离株，法国，2024 年

IF 9.9 2区医学 Q1 INFECTIOUS DISEASES

Eurosurveillance Pub Date : 2024-08-01 DOI:10.2807/1560-7917.es.2024.29.31.2400459

Carla Rodrigues, Valérie Bouchez, Anaïs Soares, Sabine Trombert-Paolantoni, Fatima Aït El Belghiti, Jérémie F Cohen, Nathalie Armatys, Annie Landier, Thomas Blanchot, Marie Hervo, REMICOQ study group, Julie Toubiana, Sylvain Brisse

{"title":"百日咳博德特氏菌重新出现，包括一个耐大环内酯的分离株，法国，2024 年","authors":"Carla Rodrigues, Valérie Bouchez, Anaïs Soares, Sabine Trombert-Paolantoni, Fatima Aït El Belghiti, Jérémie F Cohen, Nathalie Armatys, Annie Landier, Thomas Blanchot, Marie Hervo, REMICOQ study group, Julie Toubiana, Sylvain Brisse","doi":"10.2807/1560-7917.es.2024.29.31.2400459","DOIUrl":null,"url":null,"abstract":"As other European countries, France is experiencing a resurgence of pertussis in 2024. Between 1 January and 31 May 2024, 5,616 (24.9%) positive Bordetella pertussis qPCR tests were identified, following a 3-year period of almost null incidence. Of 67 cultured and whole genome sequenced B. pertussis isolates, 66 produced pertactin and 56 produced FIM2, in contrast to pre-COVID-19 years. One isolate of genotype Bp-AgST4 was resistant to macrolides. Pertussis resurgence may favour isolates that produce FIM2 and pertactin.","PeriodicalId":12161,"journal":{"name":"Eurosurveillance","volume":"78 1","pages":""},"PeriodicalIF":9.9000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Resurgence of Bordetella pertussis, including one macrolide-resistant isolate, France, 2024\",\"authors\":\"Carla Rodrigues, Valérie Bouchez, Anaïs Soares, Sabine Trombert-Paolantoni, Fatima Aït El Belghiti, Jérémie F Cohen, Nathalie Armatys, Annie Landier, Thomas Blanchot, Marie Hervo, REMICOQ study group, Julie Toubiana, Sylvain Brisse\",\"doi\":\"10.2807/1560-7917.es.2024.29.31.2400459\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"As other European countries, France is experiencing a resurgence of pertussis in 2024. Between 1 January and 31 May 2024, 5,616 (24.9%) positive Bordetella pertussis qPCR tests were identified, following a 3-year period of almost null incidence. Of 67 cultured and whole genome sequenced B. pertussis isolates, 66 produced pertactin and 56 produced FIM2, in contrast to pre-COVID-19 years. One isolate of genotype Bp-AgST4 was resistant to macrolides. Pertussis resurgence may favour isolates that produce FIM2 and pertactin.\",\"PeriodicalId\":12161,\"journal\":{\"name\":\"Eurosurveillance\",\"volume\":\"78 1\",\"pages\":\"\"},\"PeriodicalIF\":9.9000,\"publicationDate\":\"2024-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Eurosurveillance\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2807/1560-7917.es.2024.29.31.2400459\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Eurosurveillance","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2807/1560-7917.es.2024.29.31.2400459","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

摘要

与其他欧洲国家一样，法国在 2024 年也出现了百日咳复发的情况。从 2024 年 1 月 1 日到 5 月 31 日，在百日咳博德特菌 qPCR 检测中发现了 5,616 例（24.9%）阳性病例，而此前 3 年的发病率几乎为零。在 67 个经培养和全基因组测序的百日咳杆菌分离物中，66 个产生了 pertactin，56 个产生了 FIM2，这与 COVID-19 前的情况截然不同。一个基因型为 Bp-AgST4 的分离株对大环内酯类药物有抗药性。百日咳复发可能有利于产生FIM2和百日咳素的分离株。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Resurgence of Bordetella pertussis, including one macrolide-resistant isolate, France, 2024

As other European countries, France is experiencing a resurgence of pertussis in 2024. Between 1 January and 31 May 2024, 5,616 (24.9%) positive Bordetella pertussis qPCR tests were identified, following a 3-year period of almost null incidence. Of 67 cultured and whole genome sequenced B. pertussis isolates, 66 produced pertactin and 56 produced FIM2, in contrast to pre-COVID-19 years. One isolate of genotype Bp-AgST4 was resistant to macrolides. Pertussis resurgence may favour isolates that produce FIM2 and pertactin.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Eurosurveillance INFECTIOUS DISEASES-

CiteScore

32.70

自引率

2.10%

发文量

430

审稿时长

3-8 weeks

期刊介绍： Eurosurveillance is a European peer-reviewed journal focusing on the epidemiology, surveillance, prevention, and control of communicable diseases relevant to Europe.It is a weekly online journal, with 50 issues per year published on Thursdays. The journal includes short rapid communications, in-depth research articles, surveillance reports, reviews, and perspective papers. It excels in timely publication of authoritative papers on ongoing outbreaks or other public health events. Under special circumstances when current events need to be urgently communicated to readers for rapid public health action, e-alerts can be released outside of the regular publishing schedule. Additionally, topical compilations and special issues may be provided in PDF format.